Listed

Immucell Corp: Form 10-Q for the period ended Sep 30, 2022

Filed with the SEC on Nov 21, 2022 and accepted by EDGAR at Nov 21, 2022, 16:06 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-07-01 to 2022-09-30$4.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2022-01-01 to 2022-09-30$14.7mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2022-07-01 to 2022-09-30$2.9mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2022-01-01 to 2022-09-30$8.0mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2022-07-01 to 2022-09-30$1.8mus-gaap:GrossProfit
Gross profit9 months2022-01-01 to 2022-09-30$6.7mus-gaap:GrossProfit
Research and development3 months2022-07-01 to 2022-09-30$1.3mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2022-01-01 to 2022-09-30$3.4mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-07-01 to 2022-09-30−$616.8kus-gaap:OperatingIncomeLoss
Operating income9 months2022-01-01 to 2022-09-30−$665.2kus-gaap:OperatingIncomeLoss
Interest expense3 months2022-07-01 to 2022-09-30$89.4kus-gaap:InterestExpense
Interest expense9 months2022-01-01 to 2022-09-30$254.9kus-gaap:InterestExpense
Income tax3 months2022-07-01 to 2022-09-30$3.9kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2022-01-01 to 2022-09-30$6.2kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-07-01 to 2022-09-30−$655.1kus-gaap:NetIncomeLoss
Net income9 months2022-01-01 to 2022-09-30−$825.9kus-gaap:NetIncomeLoss
Diluted EPS3 months2022-07-01 to 2022-09-30−$0.08us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2022-01-01 to 2022-09-30−$0.11us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-07-01 to 2022-09-30−$0.08us-gaap:EarningsPerShareBasic
Basic EPS9 months2022-01-01 to 2022-09-30−$0.11us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-07-01 to 2022-09-307,746,864 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2022-01-01 to 2022-09-307,744,534 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2022-01-01 to 2022-09-30−$246.0kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2022-01-01 to 2022-09-30$2.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-09-30$8.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-09-30$16.4mus-gaap:AssetsCurrent
Total assetsAt period end2022-09-30$46.4mus-gaap:Assets
Current liabilitiesAt period end2022-09-30$2.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-09-30$14.4mus-gaap:Liabilities
Long-term debtAt period end2022-09-30$10.5mus-gaap:LongTermDebt
Shareholders' equityAt period end2022-09-30$32.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-22-074215. Last ingested by Listed: Nov 13, 2026, 16:08 ET. Listed shows no prices and gives no investment advice.